Mithridate

Mithridate is a Belgian biotechnology start-up company founded in 2023 and based in Genk, specializing in the field of thrombosis and hemostasis. The company designs and engineers innovative therapeutic proteins using an AI-assisted single domain antibody (sdAb or nanobody) conjugation platform. Mithridate's pipeline features three pre-clinical programs: a factor Xa inhibitor reversal program to manage severe bleeding, a dual-action therapeutic protein (MIT-2002) for Thrombotic Thrombocytopenic Purpura (TTP), and an enhanced thrombolytics program utilizing a fibrin-specific single-domain antibody fused with urokinase (uPA). Through a close collaboration with the Synapse Research Institute in Maastricht, Netherlands, Mithridate leverages advanced molecular tools and extensive hemostasis expertise to develop safer, more effective, and cost-efficient treatments for life-threatening clotting and bleeding disorders.